Spots Global Cancer Trial Database for Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications

Official Title: Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications

Study ID: NCT06321692

Conditions

Neuroendocrine Tumors

Interventions

Evaluation of blood levels of biomarkers of cardiac damage

Study Description

Brief Summary: This study is for patients with neuroendocrine tumours (NET) with or without carcinoid syndrome followed by NET Unit of European Institute of Oncology. The objective of the trial is to evaluate biochemical markers of myocardial injury (high-sensitive troponins), haemodyinamic markers (pro-brain natriuretic peptide (BNP), N-terminal (NT)-BNP (NT-proBNP)), and markers of fibrosis (Suppression of Tumorigenicity 2 (ST2) in patients with neuroendocrine tumours (NET) with or without carcinoid syndrome.

Detailed Description: The main aim of this study is to evaluate blood levels of biomarkers of cardiac damage (ultra-sensitive troponin I), hemodynamic impairment (BNP, NT-proBNP), and cardiac fibrosis (ST2) in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome The secondary objective is to correlate the levels of the above markers with the presence/entity of cardiac involvement and its progression over time. All patients will undergo: * a baseline assessment including: * blood sampling for US-Troponin I, BNP, NT-proBNP, ST2 * cardiological evaluation including ECG and echocardiogram * a three-monthly revaluation of these markers * a six monthly cardiological reassessment with a echocardiogram